| Justin Stephens, | |
|
1 Atwell Rd, Cooperstown, NY 13326-1301 | |
| (607) 547-3909 | |
| Not Available |
| Full Name | Justin Stephens |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 5 Years |
| Location | 1 Atwell Rd, Cooperstown, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184273963 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Virginia University Hospitals | Morgantown, WV | Hospital |
| Garrett County Memorial Hospital | Oakland, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Virginia University Medical Corporation | 1052224565 | 1613 |
| Specialty Physicians Of Garrett County, Llc | 5698082436 | 52 |
News Archive
Globally, Brazil has been the hardest hit by the current Zika outbreak. Almost all cases of Zika-associated malformations in newborns have been reported from this country
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
Synovis Life Technologies, Inc., has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company's well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels.
Researchers from the Swedish Defense Research Agency (FOI) and Umeå University wanted to improve the treatment of nerve agent poisoning.
Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Justin Stephens, 1 Atwell Rd, Cooperstown, NY 13326-1301 Ph: (607) 547-3909 | Justin Stephens, 1 Atwell Rd, Cooperstown, NY 13326-1301 Ph: (607) 547-3909 |
News Archive
Globally, Brazil has been the hardest hit by the current Zika outbreak. Almost all cases of Zika-associated malformations in newborns have been reported from this country
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
Synovis Life Technologies, Inc., has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler®, an innovative extension of the company's well-established Microvascular Anastomotic Coupler used in several surgical procedures to connect small blood vessels more quickly and with equal or greater reliability than hand suturing. The Flow Coupler incorporates Doppler technology to immediately measure blood flow after connecting the small blood vessels.
Researchers from the Swedish Defense Research Agency (FOI) and Umeå University wanted to improve the treatment of nerve agent poisoning.
Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
› Verified 1 days ago
Kyle Nick, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3456 | |
Kara Jane Young, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3456 | |
Melissa Erin Grey, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-4762 | |
Jessie Welch, R.P.A.C. Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3468 Fax: 607-547-4786 | |
David M Lott, P.A. Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3468 Fax: 607-547-6551 | |
James Dewey, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-6672 Fax: 607-547-6553 | |
Jennifer Branigan, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-4762 Fax: 607-547-4719 |